Verastem Reports Q3 2026 Revenue Growth and Positive Clinical Data for VS-7375
Verastem (VSTM) reported significant financial growth in its third quarter of 2026, with net product revenue reaching $24 million, a 114% increase compared to the same period last year. This surge was driven by expanded prescribing and strong refill rates for its lead oncology products. Despite the revenue jump, the company reported a non-GAAP adjusted net loss of $72.8 million ($0.72 per share), largely due to increased R&D spending on clinical trials and commercial operations. The company provided highly encouraging clinical updates for its VS-7375 program, specifically highlighting a 50% overall response rate in pancreatic cancer patients, which significantly exceeds industry benchmarks. With a pro forma cash balance of $422.8 million following an October follow-on offering, Verastem expects its current funding to support operations and clinical milestones through the first half of 2028.
Tickers: $VKTX
Topics: cash balance clinical trial results net loss pancreatic cancer treatment revenue growth